|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum IL-6, TNFα and CRP levels in Greek colorectal cancer patients: Prognostic implications显示文摘AIM: The significance of preoperative serum IL-6, TNFαand CRP levels in the progression of colorectal cancer (CRC) has not been fully elucidated. Our intention was to investigate their role and identify their prognostic significance.METHODS: The IL-6, TNFα and CRP levels were measured in 74 CRC patients and the relationships between their elevation s and both the clinicopathological factors and prognosis of patients were investigated. Serum concentrations of human IL-6 and TNFα were determined by enzyme-linked immunosorbent assay (ELISA). CRP was measured by an immunoturbinometric method.RESULTS: Median IL-6, TNFα and CRP levels weresignificantly higher in CRC patients than in normal controls.High levels of serum IL-6, TNFα and CRP were correlated with larger tumor size. Furthermore, high IL-6 and high CRP levels were associated with reduced overall survival.CONCLUSION: Serum IL-6, TNFα and CRP levels definitely increase in CRC patients. Pre-operative serum elevation of IL-6 and CRP was thus found to be predictor of the prognosis of CRC patients. The clinical value of TNFα in CRC needs to be further investigated. | Nikolaos I. Nikiteas Nikolaos Tzanakis Maria Gazouli George Rallis Kessaris Daniilidis George Theodoropoulos Alkiviadis Kostakis George Peros | 2005 | World Journal of Gastroenterology2005，11，11： | 23 |
| 2 | Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology显示文摘AIM:To assess human epidermal growth factor receptor-2 (HER2)-status in gastric cancer and matched lymph node metastases by immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH).METHODS:120 cases of primary gastric carcinomas and 45 matched lymph node metastases from patients with full clinicopathological features were mounted onto multiple-punch and single-punch tissue microarrays,respectively,and examined for HER2 overexpression and gene amplification by IHC and CISH.RESULTS:Twenty-four tumors (20%) expressed HER2 immunohistochemically.An IHC score of ≥ 2+ was observed in 20 tumors (16.6%).HER2 amplification was detected by CISH in 19 tumors (15.8%) and in their matched lymph node metastases.A high concordancerate was found between HER2 positivity (as detected by IHC) and HER2 gene amplification (as detected by CISH),since 19 of the 20 IHC positive cases were amplified (95%).All amplified cases had 2+ or 3+ IHC results.Amplification was associated with intestinal phenotype (P < 0.05).No association with grading,staging or survival was found.CONCLUSION:In gastric cancer,HER2 amplification is the main mechanism for HER2 protein overexpression and is preserved in lymph node metastases. | Dimitrios Tsapralis Ioannis Panayiotides George Peros Theodore Liakakos Eva Karamitopoulou | 2012 | World Journal of Gastroenterology2012，18，2： | 8 |
| 3 | TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer显示文摘BACKGROUND Patients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy, gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify patients with CRC who may benefit from adjuvant chemotherapy. Molecular profiling could guide treatment decisions in these patients. Thymidylate synthase (TYMS) gene polymorphisms, KRAS and BRAF could be included in the molecular profile under consideration. AIM To investigate the association of TYMS gene polymorphisms, KRAS and BRAF mutations with survival of CRC patients treated with chemotherapy.METHODS A retrospective study studied formalin-fixed paraffin-embedded tissues (FFPEs) of consecutive patients treated with adjuvant chemotherapy during January/2005-January/2007. FFPEs were analysed with PCR for the detection of TYMS polymorphisms, mutated KRAS (mKRAS) and BRAF (mBRAF). Patients were classified into three groups (high, medium and low risk) according to 5’UTR TYMS polymorphisms Similarly, based on 3’UTR polymorphism ins/loss of heterozygosity (LOH) patients were allocated into two groups (high and low risk of relapse, respectively). Cox regression models examined the associated 5- year survival outcomes. RESULTS One hundred and thirty patients with early stage CRC (stage I-II: 55 patients;stage III 75 patients;colon: 70 patients;rectal: 60 patients) were treated with surgery and chemotherapy. The 5-year disease free survival and overall survival rate was 61.6% and 73.9% respectively. 5’UTR polymorphisms of intermediate TYMS polymorphisms (2RG/3RG, 2RG/LOH, 3RC/LOH) were associated with lower risk for relapse [hazard ratio (HR) 0.320, P = 0.02 and HR 0.343, P = 0.013 respectively] and death (HR 0.368, P = 0.031 and HR 0.394, P = 0.029 respectively). The 3’UTR polymorphism ins/LOH was independently associated with increased risk for disease recurrence (P = 0.001) and death (P = 0.005). mBRAF (3.8% of patients) was associated with increased risk of death (HR 4.500, P = 0.022) whereas mKRAS (39% of patients) not. CONCLUSION Prospective validating studies are required to confirm whether 2RG/3RG, 2RG/LOH, 3RC/LOH, absence of ins/LOH and wild type BRAF may indicate patients at lower risk of relapse following adjuvant chemotherapy. | Anastasios Ntavatzikos Aris Spathis Paul Patapis Nikolaos Machairas Georgia Vourli George Peros Iordanis Papadopoulos Ioannis Panayiotides Anna Koumarianou | 2019 | World Journal of Gastrointestinal Oncology2019，11，7： | 5 |
| 4 | Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer显示文摘AIM To investigate the impact of thymidylate synthase(TYMS), KRAS and BRAF in the survival of metastatic colorectal cancer(m CRC) patients treated with chemotherapy. METHODS Clinical data were collected retrospectively from records of consecutive patients with m CRC treated with fluoropyrimidine-based chemotherapy from 1/2005 to 1/2007. Formalin-fixed paraffin-embedded tissues were retrieved for analysis. TYMS genotypes were identified with restriction fragment analysis PCR, while KRAS and BRAF mutation status was evaluated using real-time PCR assays. TYMS gene polymorphisms of each of the 3' untranslated region(UTR) and 5'UTR were classified into three groups according to the probability they have for high, medium and low TYMS expression(and similar levels of risk) based on evidence from previous studies. Univariate and multivariate survival analyses were performed.RESULTS The analysis recovered 89 patients with m CRC(46.1% de novo metastatic disease and 53.9% relapsed). Of these, 46 patients(51.7%) had colon cancer and 43(48.3%) rectal cancer as primary. All patients were treated with fluoropyrimidine-based chemotherapy(5FU or capecitabine) as single-agent or in combination with irinotecan or/and oxaliplatin or/and bevacizumab. With a median follow-up time of 14.8 mo(range 0-119.8), 85 patients(95.5%) experienced disease progression, and 63 deaths(70.8%) were recorded. The 3-year and 5-year OS rate was 25.4% and 7.7% while the 3-year progression-free survival rate was 7.1%. Multivariate analysis of TYMS polymorphisms, KRAS and BRAF with clinicopathological parameters indicated that TYMS 3'UTR polymorphisms are associated with risk for disease progression and death(P < 0.05 and P < 0.03 respectively). When compared to tumors without any del allele(genotypes ins/ins and ins/loss of heterozygosity(LOH) linked with high TYMS expression) tumors with del/del genotype(low expression group) and tumors with ins/del or del/LOH(intermediate expression group) have lower risk for disease progression(HR = 0.432, 95%CI: 0.198-0.946, P < 0.04 and HR = 0.513, 95%CI: 0.287-0.919, P < 0.03 respectively) and death(HR = 0.366, 95%CI: 0.162-0.827, P < 0.02 and HR = 0.559, 95%CI: 0.309-1.113, P < 0.06 respectively). Additionally,KRAS mutation was associated independently with the risk of disease progression(HR = 1.600, 95%CI: 1.011-2.531, P < 0.05). The addition of irinotecan in 1st line chemotherapy was associated independently with lower risk for disease progression and death(HR = 0.600, 95%CI: 0.372-0.969, P < 0.04 and HR = 0.352, 95%CI: 0.164-0.757, P < 0.01 respectively).CONCLUSION The TYMS genotypes ins/ins and ins/LOH associate with worst prognosis in m CRC patients under fluoropyrimidine-based chemotherapy. Large prospective studies are needed for validation of our findings. | Anastasios Ntavatzikos Aris Spathis Paul Patapis Nikolaos Machairas George Peros Stefanos Konstantoudakis Danai Leventakou Ioannis G Panayiotides Petros Karakitsos Anna Koumarianou | 2017 | World Journal of Gastroenterology2017，23，32： | 4 |
| 5 | Asymptomatic Cholelithiasis: Is Cholecystectomy Really Needed? A Critical Reappraisal 15 Years After the Introduction of Laparoscopic Cholecystectomy显示文摘 | George H. Sakorafas Dimitrios Milingos George Peros | 2007 | Digestive Diseases and Sciences2007，，5： | 2 |
| 6 | Mechanisms and Natural History of Pain in Chronic Pancreatitis: A Surgical Perspective显示文摘 | George H. Sakorafas Adelais G. Tsiotou George Peros | 2007 | Journal of Clinical Gastroenterology2007，，7： | 2 |
| 7 | Asymptomatic Cholelithiasis: Is Cholecystectomy Really Needed? A Critical Reappraisal 15 Years After the Introduction of Laparoscopic Cholecystectomy显示文摘 | George H. Sakorafas Dimitrios Milingos George Peros | 2007 | Digestive Diseases and Sciences2007，，5： | 1 |
| 8 | Celiac Artery Stenosis: An Underappreciated and Unpleasant Surprise in Patients Undergoing Pancreaticoduodenectomy显示文摘 | George H. Sakorafas Michael G. Sarr George Peros | 2008 | Journal of the American College of Surgeons2008，，2： | 1 |
| 9 | Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer显示文摘 | Eva Karamitopoulou Inti Zlobec Ioannis Panayiotides Efstratios S. Patsouris George Peros George Rallis Christos Lapas Petros Karakitsos Luigi M. Terracciano Alessandro Lugli | 2011 | Human Pathology2011，，12： | 1 |
| 10 | Lymphedema following axillary lymph node dissection for breast cancer显示文摘 | George H.Sakorafas George Peros Luigi Cataliotti | | 0，，15： | 1 |
| 11 | 阿梅格尔巴克/哥本山显示文摘垃圾焚烧发电厂阿梅格尔巴克/哥本山位于工业区,多年来,该工业区已成为冒险者们的极限运动目的地。原始的工业设施为各种极限运动活动提供了场所,如缆绳滑水、卡丁车和攀岩等。阿梅格尔巴克/哥本山是该地区最重要的地标,其建筑亟须更新。我们提出了一种新型的垃圾焚烧发电厂,这种工厂能产生经济、环保和社会效益。 | Nanna Gyldholm M■ller Alberto Cumerlato Aleksander Wadas Alexander Codda Alexander Ejsing Alexandra Gustafsson Alina Tamosiunaite Armor Gutierrez Anders Hjortn■s Andreas Klok Pedersen Annette Jensen Ariel Wallner Ask Andersen Balaj IIulian Blake Smith Borko Nikolic Brygida Zawadzka Buster Christensen Chris Falla Chris Zhongtian Yuan Daniel Selensky Dennis Rasmussen Espen Vik Finn N■rkj■r Franck Fdida Gonzalo Castro Gül Ertekin George Abraham Helen Chen Henrick Poulsen Henrik R■mer Kania Horia Spirescu Jakob Ohm Laursen Jelena Vucic Jeppe Ecklon Ji-young Yoon Jing Xu Joanna Jakubowska Johanna Nenander Kamilla Heskje Katarzyna Siedlecka Krzysztof Marciszewski Laura W■tte Liang Wang Lise Jessen Long Zuo Maciej Zawadzki Mads Enggaard Stidsen Marcelina Kolasinska Marcos Bano Maren Allen Mathias Bank Matti N■rgaard Michael Andersen Narisara Ladawal Schr■der Niklas A.Rasch Nynne Madsen ■ssur Nols■ Pero Vukovic Richard Howis Ryohei Koike Se Hyeon Kim Simon Masson Sunming Lee Toni Mateu Xing Xiong Zoltan David Kalaszi Rasmus Hjortshoj 陈子钰(译) | 2019 | 城市环境设计2019，0，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员